Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 108 of the 108 references it cites were found in a registry or an index; 67 of the 164 sources its claims cite were checked for support.

Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings

Open access
Harvey, R Donald, Adams, Val R, Beardslee, Tyler, Medina, Patrick · 2020 · Journal of Oncology Pharmacy Practice

Abstract

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors represent the standard of care in patients with EGFR mutation-positive NSCLC. This review summarizes the pharmacology, efficacy, safety, and treatment sequencing of afatinib.

Overview

CoChat Summary

TL;DR

This narrative review summarizes the pharmacology, efficacy, safety, and sequencing of afatinib in EGFR mutation-positive NSCLC, drawing mainly on the LUX-Lung clinical trial program. It concludes that afatinib improves PFS over chemotherapy and gefitinib in first-line EGFRm+ NSCLC and has activity in certain uncommon EGFR mutations and brain metastases, while adverse events are manageable with tolerability-guided dose adjustment.

Key findings

  • Afatinib is an oral, irreversible ErbB-family blocker given at 40 mg once daily; a high-fat meal reduces AUC from 676 to 414 ng·h/ml, so it should be taken on an empty stomach. Elimination half-life is 37 h after repeat dosing, and steady state is reached within 8 days.
  • In LUX-Lung 3 and 6, afatinib improved median PFS versus chemotherapy: 11.1 vs 6.9 months (HR 0.58, 95% CI 0.43–0.78, P=0.001) and 11.0 vs 5.6 months (HR 0.28, 95% CI 0.20–0.39, P<0.0001). Combined OS was not significantly improved (25.8 vs 24.5 months; HR 0.91, 95% CI 0.75–1.11, P=0.37), but Del19-positive patients had prolonged OS in both trials.
  • In LUX-Lung 7 versus gefitinib, afatinib improved PFS (11.0 vs 10.9 months; HR 0.73, 95% CI 0.57–0.95, P=0.017), TTF (13.7 vs 11.5 months; HR 0.73, 95% CI 0.58–0.92, P=0.007), and ORR (70% vs 56%; P=0.0083), with grade ≥3 treatment-related AEs higher for afatinib (31.3% vs 17.6%).
  • In a pooled analysis of uncommon mutations (n=75), median PFS was 13.8 months for G719X, 8.2 months for L861Q, and 14.7 months for S768I, with ORR 78%, 56%, and 100%, respectively; afatinib was not active against T790M or exon 20 insertions. In LUX-Lung 8 for squamous NSCLC, afatinib improved PFS (2.6 vs 1.9 months; HR 0.81, 95% CI 0.69–0.96, P=0.0103) and OS (7.9 vs 6.8 months; HR 0.81, 95% CI 0.69–0.95, P=0.0077) versus erlotinib.

Methods

  • Narrative review of afatinib in EGFRm+ NSCLC, covering pharmacology, efficacy, safety, acquired resistance, treatment sequencing, and cost-effectiveness.
  • Data sources cited include the LUX-Lung 2, 3, 6, 7, and 8 trials, real-world studies, and pharmacoeconomic analyses; no new primary patient data are presented.
  • Main analysis is a narrative synthesis of published trial and real-world results, including pooled subgroup analyses for uncommon EGFR mutations and baseline brain metastases; no systematic search or formal meta-analysis methodology is described.

Limitations

  • Stated: the optimal EGFR TKI sequencing strategy remains under debate; head-to-head studies, including afatinib versus osimertinib, are needed, and additional studies are required for T790M-negative resistance and further pharmacoeconomic confirmation.
  • Stated: patients with brain metastases have been excluded from clinical trials, limiting generalizability; little is known about afatinib brain penetrance in humans, and preclinical rat studies suggest low brain distribution.
  • Evident from the text: as a narrative review, it does not describe a systematic literature search or inclusion criteria, and some sections in the provided text appear incomplete or empty (e.g., squamous cell carcinoma and summary headings), so the summary relies on the cited trials rather than a transparent evidence-synthesis protocol.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1177/1078155220931926

Cites

108 of 108 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1. Inhibition of ErbB family members, including WT and mutant EGFR, by afatinib. EGFR: epidermal growth factor receptor; WT: wild-type.
Figure 1. Inhibition of ErbB family members, including WT and mutant EGFR, by afatinib. EGFR: epidermal growth factor receptor; WT: wild-type.CC BY-NC · PubMed Central
Figure 2. Competing risk analysis for progression in afatinib-treated patients with baseline brain metastases ((a) LUX-Lung 3 and 6) and without baseline brain metastases ((b) LUX-Lung 3, 6, and 7). CNS: central nervous system; NSCLC: non-small cell lung cancer; PD: progressive disease. Reproduced under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International Public License (Girard et al.).30
Figure 2. Competing risk analysis for progression in afatinib-treated patients with baseline brain metastases ((a) LUX-Lung 3 and 6) and without baseline brain metastases ((b) LUX-Lung 3, 6, and 7). CNS: central nervous system; NSCLC: non-small cell lung cancer; PD: progressive disease. Reproduced under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International Public License (Girard et al.).30CC BY-NC · PubMed Central
Figure 3. Potential treatment strategies following acquired resistance to afatinib. (a) Investigational therapy100; (b) platinum-doublet chemotherapy represents the principal treatment option outside of the clinical trial setting103; (c) this combination showed considerable efficacy in EGFRm+ NSCLC but has not yet been investigated specifically in patients with EGFRm+ T790M-negative tumors109; and (d) Investigational treatment options with some activity in EGFRm+ NSCLC in early-phase studies.103,105–108EGFR: epidermal growth factor receptor; EGFRm+: EGFR mutation-positive; NSCLC: non-small cell lung cancer; TKI: tyrosine kinase inhibitor.
Figure 3. Potential treatment strategies following acquired resistance to afatinib. (a) Investigational therapy100; (b) platinum-doublet chemotherapy represents the principal treatment option outside of the clinical trial setting103; (c) this combination showed considerable efficacy in EGFRm+ NSCLC but has not yet been investigated specifically in patients with EGFRm+ T790M-negative tumors109; and (d) Investigational treatment options with some activity in EGFRm+ NSCLC in early-phase studies.103,105–108EGFR: epidermal growth factor receptor; EGFRm+: EGFR mutation-positive; NSCLC: non-small cell lung cancer; TKI: tyrosine kinase inhibitor.CC BY-NC · PubMed Central

Verification

Claims the paper makes

51 Valid · 1 Not valid · 42 Not checked · 8 Own results and interpretations

59 more claims · 31 with their cited sources checked

Create a free account to see all 102 claims and to verify the 9 references still open.

See all claims — free account
  • Probably not a substantial claim. 8
  • It may state two separate claims as one. 33

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 108 references

Research works printed but not linked: 3

  1. Chan BA, 2015, Transl Lung Cancer Res, 4, 36
  2. Davies RSS, 2017, Lung Cancer Int, 9614938
  3. Graham J, 2018, J Manag Care Spec Pharm, 24, 544

Cited by

See all 115

Metadata

Authors
Harvey, R. D., Adams, V. R., Beardslee, T., & Medina, P.
Affiliations
  • Emory University (US)
  • University of Kentucky (US)
  • Winship Cancer Institute (US)
  • OU Health Stephenson Cancer Center (US)
Corresponding author
Harvey, R Donald
Venue
Journal of Oncology Pharmacy Practice
Published
2020-06-20
Volume
26
Issue
6
Pages
1461-1474
ISSN
  • 1078-1552 (ISSN-L)
  • 1477-092X
OpenAlex
W3036183865
Cited by
115
References
108
Citations by year
2026: 14 · 2025: 19 · 2024: 30 · 2023: 22 · 2022: 21 · 2021: 7 · 2020: 2
FWCI
1.86
Type
journal article
Language
en
Open access
Locations
  • Journal of Oncology Pharmacy Practice (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • UKnowledge (University of Kentucky) (submittedVersion, cc-by-nc)
Funders
Boehringer Ingelheim
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
  • Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Keywords
afatinib, EGFR-mutant non-small cell lung cancer, EGFR tyrosine kinase inhibitors, gefitinib, brain metastases, treatment resistance mechanisms, dose adjustment, adverse events, economic impact, treatment sequencing
MeSH terms
Gefitinib, Afatinib, Progression-Free Survival, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Humans, Lung Neoplasms, Mutation, Protein Kinase Inhibitors, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings. https://app.cochat.ai/papers/10.1177/1078155220931926
The paper
Harvey, R. D., Adams, V. R., Beardslee, T., & Medina, P. (2020). Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings. Journal of Oncology Pharmacy Practice. https://doi.org/10.1177/1078155220931926

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.